Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 8

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 8
Chunk 8
---
 by and between Phoenix Biotech Sponsor, LLC and CERo Therapeutics Holdings, Inc. (incorporated by reference to Exhibit 10.11 to the Current Report on Form 8-K/A filed by CERo Therapeutics Holdings, Inc. with the Securities and Exchange Commission on February 27, 2024).

    10.14
     
    Side Letter, dated as of February 14, 2024, by and between Phoenix Biotech Acquisition Corp. and
    the Lead Investor (incorporated by reference to Exhibit 10.12 to the Current Report on Form 8-K/A filed by CERo Therapeutics Holdings,
    Inc. with the Securities and Exchange Commission on February 27, 2024).

    10.15
     
    Securities Purchase Agreement, dated as of March 29, 2024, by and between CERo Therapeutics Holdings,
    Inc. and the investors named therein (incorporated by reference to Exhibit 10.13 to the Annual Report on Form 10-K filed by CERo
    Therapeutics Holdings, Inc. with the Securities and Exchange Commission on April 2, 2024).

115

    10.16
     
    Registration Rights Agreement, dated as of March 29, 2024, by and between CERo Therapeutics Holdings, Inc. and the investors party thereto (incorporated by reference to Exhibit 10.14 to the Annual Report on Form 10-K filed by CERo Therapeutics Holdings, Inc. with the Securities and Exchange Commission on April 2, 2024).

    10.17+
     
    Consulting Agreement, dated September 30, 2024, by and between the Company and Kristen Pierce (incorporated
    by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by CERo Therapeutics Holdings, Inc. with the Securities and
    Exchange Commission on October 2, 2024).

    10.18+
     
    Consulting Agreement, dated September 30, 2024, by and between the Company and Andrew Kucharchuk
    (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed by CERo Therapeutics Holdings, Inc. with the Securities
    and Exchange Commission on October 2, 2024).

    10.19+
     
    Consulting Agreement, dated